Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg)

This 12mg blend combines Fragment 176-191 6mg, CJC-1295 3mg, and Ipamorelin 3mg in a single vial, synthesized and lyophilized in the USA.

Each vial of Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg) contains a pre-weighed ratio of Fragment 176-191 6mg, CJC-1295 3mg, Ipamorelin 3mg in a single lyophilized cake, simplifying multi-peptide research protocols.

Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg) is commonly included in metabolic research panels investigating appetite-regulating pathways and energy homeostasis in laboratory models.

Studies evaluating Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg) typically focus on receptor activation profiles and downstream metabolic signaling under controlled in-vitro conditions.

Researchers using Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg) often combine dose-response assays with stability testing to establish reproducible experimental baselines.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Fragment 176-191 & CJC-1295 & Ipamorelin Blend (12mg). Summaries are provided for orientation only and reflect the cited sources.

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice^[1] — This study examined how chronic treatment with human growth hormone and its C-terminal lipolytic fragment AOD9604 (a modified form of the hGH 177-191 region) affects lipid metabolism in obese mice. The work also used beta(3)-adrenergic receptor knockout mice to probe the receptor pathways involved in the fragment's fat-mobilizing actions. The findings suggested that this GH-derived fragment may exert lipid-lowering effects relevant to the lipolytic domain shared with Fragment 176-191. (Endocrinology 2001)

Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone^[2] — This paper reported metabolic investigations of AOD9604, a synthetic peptide corresponding to the lipolytic domain of human growth hormone. The studies characterized the peptide's ability to modulate fat metabolism in experimental models. The results indicated that this region of the GH molecule retains metabolic activity that may be relevant to the action of related lipolytic fragments such as Fragment 176-191. (Hormone Research 2000)

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults^[3] — This clinical study evaluated how a single injection of CJC-1295, a long-acting analog of growth hormone-releasing hormone, affects GH and IGF-I secretion in healthy adults. The authors examined the duration and magnitude of the hormonal response to the modified GHRH peptide. The results suggested that CJC-1295 can produce sustained elevations of GH and IGF-I, supporting its characterization as a long-acting GHRH analog. (The Journal of Clinical Endocrinology & Metabolism 2006)

Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog^[4] — This study investigated whether continuous stimulation with the long-acting GHRH analog CJC-1295 preserves the natural pulsatile pattern of growth hormone secretion. Healthy men were studied during ongoing exposure to the peptide to assess both trough and peak GH dynamics. The findings indicated that GH pulsatility persists even under continuous GHRH analog stimulation, while baseline levels were elevated. (The Journal of Clinical Endocrinology & Metabolism 2006)

Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats^[5] — This study tested whether the novel growth-hormone-releasing peptide ipamorelin can stimulate longitudinal bone growth in rats. The authors examined the peptide's effects on skeletal growth over the study period. The results suggested that ipamorelin promotes bone elongation, consistent with its GH-releasing activity. (Growth Hormone & IGF Research 1999)

Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption^[6] — This pharmacokinetic study evaluated ipamorelin and other peptidyl growth hormone secretagogues, with particular attention to their absorption after nasal administration. The authors compared the pharmacokinetic profiles of these peptides to assess their suitability for non-invasive delivery. The findings indicated that nasal absorption characteristics vary among the secretagogues examined. (Xenobiotica 1999)

References

1. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology. 2001. pubmed.ncbi.nlm.nih.gov/11713213/
2. Ng FM, et al.. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Hormone Research. 2000. pubmed.ncbi.nlm.nih.gov/11146367/
3. Teichman SL, et al.. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/3/799/10779632/jcem0799.p…
4. Ionescu M, Frohman LA. "Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/12/4792/9059878/jcem4792.…
5. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Hormone & IGF Research. 1999. pubmed.ncbi.nlm.nih.gov/10373343/
6. Johansen PB, Hansen KT, Andersen JV, Johansen NL. "Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption." Xenobiotica. 1999. pubmed.ncbi.nlm.nih.gov/9879640/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.